VVP
VRTX icon

Venture Visionary Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Venture Visionary Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$415K Sell
793
-196
-20% -$100K 0.01% 503
2026
Q2 		$491K Buy
989
+301
+44% +$133K 0.01% 476
2026
Q1 		$307K Sell
688
-466
-40% -$217K 0.01% 508
2025
Q4 		$523K Buy
1,154
+197
+21% +$84.9K 0.02% 423
2025
Q3 		$375K Buy
957
+263
+38% +$110K 0.01% 476
2025
Q2 		$309K Buy
694
+5
+0.7% +$2.3K 0.01% 479
2025
Q1 		$334K Sell
689
-1
-0.1% -$466 0.01% 450
2024
Q4 		$278K Buy
690
+4
+0.6% +$1.85K 0.01% 465
2024
Q3 		$319K Sell
686
-1
-0.1% -$480 0.01% 446
2024
Q2 		$322K Buy
687
+14
+2% +$6.08K 0.01% 450
2024
Q1 		$281K Sell
673
-9
-1% -$3.81K 0.01% 459
2023
Q4 		$277K Buy
682
+10
+1% +$3.69K 0.01% 444
2023
Q3 		$234K Sell
672
-4
-0.6% -$1.4K 0.01% 447
2023
Q2 		$238K Sell
676
-5
-0.7% -$1.69K 0.01% 454
2023
Q1 		$215K Buy
+681
New +$204K 0.01% 461
2022
Q3 		– Sell
-339
Closed -$95.5K – 1521
2022
Q2 		$95.5K Buy
+339
New +$90.7K 0.01% 618

Other funds holding VRTX

MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.76B AUM 33.82% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GGS
Galvin Gaustad & Stein Scottsdale, Arizona $1.33B AUM 13.15% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
LJHT
Laurie J. Hall Trustee $314M AUM 27.43% 1-Year Est. Return
CFG
Cooper Financial Group Irvine, California $1.26B AUM 21.18% 1-Year Est. Return

Venture Visionary Partners's VRTX Position: Q3 2026 in Review

Venture Visionary Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q3 2026, selling an estimated $100K and leaving 793 shares worth $415K. The position accounts for 0.01% of the portfolio, ranked #503.

Venture Visionary Partners first reported a position in VRTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $523K in Q4 2025. 66 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Venture Visionary Partners held 793 shares of Vertex Pharmaceuticals worth $415K as of Q3 2026.
  • Venture Visionary Partners sold 196 Vertex Pharmaceuticals shares in Q3 2026, an estimated $100K.
  • Vertex Pharmaceuticals made up 0.01% of Venture Visionary Partners's portfolio in Q3 2026, its #503 holding.
  • Venture Visionary Partners first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Venture Visionary Partners's Vertex Pharmaceuticals position peaked at $523K in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Venture Visionary Partners's 13F filing for Q3 2026, filed 7 Oct 2026.